ARS Pharmaceuticals, Inc. (SPRY) Stock

Healthcare · Biotechnology · Member of Other US Stocks

ARS Pharmaceuticals, Inc. (SPRY) closed at USD 4.07 on 2026-10-15, a change of -54.7 % over the past year, with a market capitalization of USD 399.78M.

ARS Pharmaceuticals, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

ARS Pharmaceuticals, Inc. key figures

Previous close

USD 4.07 (2026-10-15)

1-year change

-54.7 %

Market cap

USD 399.78M

Enterprise value

USD 427.54M

P/E ratio (trailing)

-1.84

P/E ratio (forward)

-4.48

EPS (trailing)

-2.18

EPS (forward)

-0.90

PEG ratio

n/a

Price to book

31.90

Revenue growth

114.2 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

14.70

Employees

195

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About ARS Pharmaceuticals, Inc.

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for ARS Pharmaceuticals, Inc. and compare it with other stocks.